NeuroOne Medical Technologies (NASDAQ:NMTC – Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02), FiscalAI reports. NeuroOne Medical Technologies had a negative return on equity of 119.92% and a negative net margin of 78.34%.The company had revenue of $2.39 million during the quarter, compared to analysts’ expectations of $2.58 million.
Here are the key takeaways from NeuroOne Medical Technologies’ conference call:
- NeuroOne reported 72% year-over-year product revenue growth in Q2 fiscal 2026 to $2.4 million, driven by higher sales of its OneRF products.
- Management highlighted continued clinical traction for the OneRF Trigeminal Nerve Ablation System, with 16 cases completed and all patients reportedly pain-free after the procedure.
- The company said it completed the stage 2 ISO 13485 audit of its Minnesota facility and remains optimistic about certification in late 2026, which would support international distribution.
- NeuroOne reaffirmed its full-year product revenue guidance of $10.5 million, noting it does not yet include meaningful contributions from drug delivery or facial pain commercialization.
- The company ended the quarter with $2.8 million in cash and no debt, while also announcing a CFO transition in which Ron McClurg will retire and Chris Volker will take over effective July 1, 2026.
NeuroOne Medical Technologies Trading Up 2.0%
NMTC stock traded up $0.09 on Tuesday, hitting $4.42. The company had a trading volume of 21,763 shares, compared to its average volume of 43,408. The stock has a market cap of $37.17 million, a price-to-earnings ratio of -4.33 and a beta of 0.60. NeuroOne Medical Technologies has a 12-month low of $3.27 and a 12-month high of $6.96. The stock’s 50-day simple moving average is $4.55 and its 200 day simple moving average is $4.56.
Wall Street Analyst Weigh In
Check Out Our Latest Research Report on NeuroOne Medical Technologies
Insider Transactions at NeuroOne Medical Technologies
In other news, insider David J. Wambeke purchased 166,666 shares of the business’s stock in a transaction on Sunday, March 1st. The stock was acquired at an average cost of $4.02 per share, for a total transaction of $669,997.32. Following the purchase, the insider directly owned 166,666 shares in the company, valued at $669,997.32. This trade represents a ∞ increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 2,438 shares of company stock valued at $11,702 over the last 90 days. Company insiders own 11.80% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. lifted its position in NeuroOne Medical Technologies by 31.2% during the third quarter. Vanguard Group Inc. now owns 1,578,237 shares of the company’s stock valued at $1,403,000 after purchasing an additional 375,639 shares in the last quarter. Renaissance Technologies LLC lifted its stake in NeuroOne Medical Technologies by 10.2% in the 4th quarter. Renaissance Technologies LLC now owns 763,028 shares of the company’s stock worth $578,000 after purchasing an additional 70,428 shares in the last quarter. Essex Investment Management Co. LLC purchased a new stake in shares of NeuroOne Medical Technologies in the fourth quarter worth about $143,000. Virtu Financial LLC purchased a new stake in shares of NeuroOne Medical Technologies during the 3rd quarter worth approximately $88,000. Finally, Goldman Sachs Group Inc. bought a new position in NeuroOne Medical Technologies during the first quarter valued at $84,000. Hedge funds and other institutional investors own 16.07% of the company’s stock.
About NeuroOne Medical Technologies
NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.
The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.
Featured Articles
- Five stocks we like better than NeuroOne Medical Technologies
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
- Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?
- Rocket Lab Just Hit a New All-Time High—Time to Buy or Let It Breathe?
Receive News & Ratings for NeuroOne Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroOne Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
